Potential treatment: Miravant regains rights to wet AMD therapy

Article

Santa Barbara, CA-Miravant Medical Technologies plans to seek new applications for its primary drug candidate, a potential therapy for wet age-related macular degeneration (AMD)

Related Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
© 2024 MJH Life Sciences

All rights reserved.